ModeX Therapeutics to present preclinical in vivo CAR-T generation data at ASGCT 2026

OPKO Health, Inc.

OPKO Health, Inc.

OPK

0.00
  • ModeX Therapeutics, an Opko Health unit, plans to present preclinical data at ASGCT 2026 showing in vivo CAR-T cell generation with its MDX3001 candidate.
  • Studies using ModeX CD3xCD28 antibody-conjugated LNP/mRNA platform showed deep systemic B-cell depletion in blood and lymphoid tissues.
  • Activity was reported in humanized mouse models and non-human primates, supporting potential use in autoimmune disease and oncology.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opko Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120800PRIMZONEFULLFEED9717679) on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.